文献速递临床试验与 GCP流行病学与生物统计

2014-2016年欧洲药品管理局批准抗癌药物所依据的随机对照试验的设计特征、偏倚风险与报告质量:横断面分析

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
PubMed 文献 · BMJ · 2019-09-18

该横断面分析评估了2014至2016年欧洲药品管理局(EMA)批准新型抗癌药物所依据的关键随机对照试验的设计特征、偏倚风险与报告充分性。研究纳入54项关键研究中的39项随机对照试验,发现仅26%以总生存期为主要或共同主要终点,49%主要结局被评为高偏倚风险,监管文件与科学文献的报告存在缺口。

要点

  • 39项随机对照试验中仅10项(26%)以总生存期为主要或共同主要终点。
  • 19项随机对照试验(49%)主要结局被评为高偏倚风险。
  • 监管文件识别出10种药物(31%)存在偏倚评估未覆盖的额外缺陷,而科学出版物未将其列为局限性。

核心结论

  • 2014至2016年EMA批准新型抗癌药物所依据的关键研究多为随机对照试验,但近半数基于设计、实施或分析被评为高偏倚风险。
  • 监管文件与科学文献的报告均存在缺口,期刊出版物未承认监管文件中识别的关键局限性。

研究设计与样本

  • 横断面分析,数据来源为欧洲监管文件、临床试验注册记录、方案、期刊发表及补充附录。
  • 纳入标准为2014至2016年EMA批准的新型抗癌药物的关键随机对照试验。
  • EMA在此期间基于54项关键研究批准了32种新型抗癌药物,其中41项(76%)为随机对照试验,13项(24%)为非随机研究或单臂研究;39/41项随机对照试验有可用发表文献并纳入分析。

主要发现

  • 仅10项随机对照试验(26%)以总生存期为主要或共同主要终点,其余评估无进展生存期和缓解率等替代指标。
  • 19项随机对照试验(49%)主要结局被评为高偏倚风险,最常见原因为缺失结局数据(n=10)和结局测量(n=7)。
  • 以总生存期为主要终点的随机对照试验中高偏倚风险比例低于以替代疗效终点者:2/10(20%)vs 16/29(55%)。
  • 分别考虑监管文件与科学文献信息时,8项随机对照试验(21%)的总体偏倚风险判断不同,反映两种信息来源的报告不足。
  • 监管机构对10种药物(31%)识别出偏倚风险评估未覆盖的额外缺陷,包括临床获益幅度、不适当对照和非优选研究终点,科学出版物未将其列为局限性。

局限性

  • 部分高偏倚风险可能因癌症试验的复杂性而不可避免。
  • 监管文件与科学文献的报告均存在缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the design characteristics, risk of bias, and reporting adequacy of pivotal randomised controlled trials of cancer drugs approved by the European Medicines Agency (EMA). DESIGN: Cross sectional analysis. SETTING: European regulatory documents, clinical trial registry records, protocols, journal publications, and supplementary appendices. ELIGIBILITY CRITERIA: Pivotal randomised controlled trials of new cancer drugs approved by the EMA between 2014 and 2016. MAIN OUTCOME MEASURES: Study design characteristics (randomisation, comparators, and endpoints); risk of bias using the revised Cochrane tool (bias arising from the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result); and reporting adequacy (completeness and consistency of information in trial protocols, publications, supplementary appendices, clinical trial registry records, and regulatory documents). RESULTS: Between 2014 and 2016, the EMA approved 32 new cancer drugs on the basis of 54 pivotal studies. Of these, 41 (76%) were randomised controlled trials and 13 (24%) were either non-randomised studies or single arm studies. 39/41 randomised controlled trials had available publications and were included in our study. Only 10 randomised controlled trials (26%) measured overall survival as either a primary or coprimary endpoint, with the remaining trials evaluating surrogate measures such as progression free survival and response rates. Overall, 19 randomised controlled trials (49%) were judged to be at high risk of bias for their primary outcome. Concerns about missing outcome data (n=10) and measurement of the outcome (n=7) were the most common domains leading to high risk of bias judgments. Fewer randomised controlled trials that evaluated overall survival as the primary endpoint were at high risk of bias than those that evaluated surrogate efficacy endpoints (2/10 (20%) v 16/29 (55%), respectively). When information available in regulatory documents and the scientific literature was considered separately, overall risk of bias judgments differed for eight randomised controlled trials (21%), which reflects reporting inadequacies in both sources of information. Regulators identified additional deficits beyond the domains captured in risk of bias assessments for 10 drugs (31%). These deficits included magnitude of clinical benefit, inappropriate comparators, and non-preferred study endpoints, which were not disclosed as limitations in scientific publications. CONCLUSIONS: Most pivotal studies forming the basis of EMA approval of new cancer drugs between 2014 and 2016 were randomised controlled trials. However, almost half of these were judged to be at high risk of bias based on their design, conduct, or analysis, some of which might be unavoidable because of the complexity of cancer trials. Regulatory documents and the scientific literature had gaps in their reporting. Journal publications did not acknowledge the key limitations of the available evidence identified in regulatory documents.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Naci H, Davis C, Savović J, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ. 2019. PMID: 31533922. doi:10.1136/bmj.l5221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。